Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.02 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,479
Open 49.02
Bid (Size) 49.07 (21)
Ask (Size) 49.15 (1)
Prev. Close 49.02
Today's Range 49.02 - 49.02
52wk Range 48.42 - 81.44
Shares Outstanding 2,222,113,553
Dividend Yield 4.65%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga

Performance

YTD
-32.16%
-32.16%
1 Month
-4.35%
-4.35%
3 Month
-20.47%
-20.47%
6 Month
-23.06%
-23.06%
1 Year
-38.06%
-38.06%

More News

Read More
3 Resilient Stocks with Massive Potential to Boost Your Wealth
Via InvestorPlace
Don't Wait for a Market Crash: These 2 Top Stocks Are on Sale
Via The Motley Fool
$1M Bet On Iridium Communications? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Exploring NYSE:BMY's dividend characteristics.
Via Chartmill
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Why Bristol Myers Squibb Stock Is Fading Today
Via The Motley Fool
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters
Via InvestorPlace
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Via Benzinga
Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade
Via InvestorPlace
Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering
Via InvestorPlace
The Latest Analyst Ratings for Bristol-Myers Squibb
Via Benzinga
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
Via InvestorPlace
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
Via Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
Via MarketBeat
Exposures Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Via Benzinga
Exposures Product Safety
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?
Via The Motley Fool
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.